Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | CLK1 | P49759 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MC4R | P32245 | 1/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL401835 | 0.92 | PAX8 (0.51) | TBXAS1GAAMEN1SLC2A1KMT2A | |
| SCHEMBL402193 | 0.91 | TBXAS1 (0.48) | TBXAS1GAAPAX8TP53MAPT | |
| SCHEMBL3659497 | 0.85 | PAX8 (0.58) | GAAMEN1SLC2A1KMT2APAX8 | |
| SCHEMBL402958 | 0.84 | GAA (0.60) | GAAMEN1SLC2A1KMT2ATP53 | |
| SCHEMBL403648 | 0.84 | PAX8 (0.68) | GAAMEN1SLC2A1KMT2APAX8 | |
| SCHEMBL402967 | 0.83 | PAX8 (0.54) | GAAMEN1SLC2A1KMT2APAX8 | |
| Hydrochloric Acid SCHEMBL15093957 | 0.83 | PAX8 (0.70) | GAAMEN1SLC2A1KMT2APAX8 | |
| SCHEMBL402972 | 0.83 | PAX8 (0.49) | GAAMEN1KMT2APAX8TP53 | |
| SCHEMBL3657702 | 0.83 | PAX8 (0.57) | GAAMEN1SLC2A1KMT2APAX8 | |
| SCHEMBL402202 | 0.81 | PAX8 (0.55) | GAAMEN1SLC2A1KMT2APAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2432764-A1 | SUBSTITUTED QUINOLINES FOR USE AS VEGF INHIBITORS | ClanoTech AB (SE) | 2012-03-28 | — | — | EP | claimed |
| US-20120065199-A1 | SUBSTITUTED QUINOLINES FOR USE AS VEGF INHIBITORS | CLANOTECH AB (SE) | 2012-03-15 | — | — | US | claimed |
| WO-2010133669-A1 | SUBSTITUTED QUINOLINES FOR USE AS VEGF INHIBITORS | CLANOTECH AB (SE) | 2010-11-25 | — | — | WO | claimed |
| US-9376393-B2 | Quinoline compounds which are anti-angiogenic integrin alpha5 beta1 inhibitors for use in the treatment of fibrosis or fibrosis-related diseases | CLANOTECH AB (SE) | 2016-06-28 | — | — | US | disclosed |
| US-9376393-B2 | Quinoline compounds which are anti-angiogenic integrin alpha5 beta1 inhibitors for use in the treatment of fibrosis or fibrosis-related diseases | CLANOTECH AB (SE) | 2016-06-28 | — | — | US | disclosed |
| US-9376393-B2 | Quinoline compounds which are anti-angiogenic integrin alpha5 beta1 inhibitors for use in the treatment of fibrosis or fibrosis-related diseases | CLANOTECH AB (SE) | 2016-06-28 | — | — | US | disclosed |
| US-20150031723-A1 | Quinoline Compounds Which Are Anti-Angiogenic Integrin Alpha5 Beta1 Inhibitors for Use in the Treatment of Fibrosis or Fibrosis-Related Diseases | CLANOTECH AB (SE) | 2015-01-29 | — | — | US | disclosed |
| US-20150031723-A1 | Quinoline Compounds Which Are Anti-Angiogenic Integrin Alpha5 Beta1 Inhibitors for Use in the Treatment of Fibrosis or Fibrosis-Related Diseases | CLANOTECH AB (SE) | 2015-01-29 | — | — | US | disclosed |
| US-20150031723-A1 | Quinoline Compounds Which Are Anti-Angiogenic Integrin Alpha5 Beta1 Inhibitors for Use in the Treatment of Fibrosis or Fibrosis-Related Diseases | CLANOTECH AB (SE) | 2015-01-29 | — | — | US | disclosed |
| WO-2013103317-A1 | QUINOLINE COMPOUNDS WHICH ARE ANTI-ANGIOGENIC INTEGRIN ALPHA5 BETAL INHIBITORS FOR USE IN THE TREATMENT OF FIBROSIS OR FIBROSIS-RELATED DISEASES | CLANOTECH AB (SE) | 2013-07-11 | — | — | WO | disclosed |
| EP-2432764-A1 | SUBSTITUTED QUINOLINES FOR USE AS VEGF INHIBITORS | ClanoTech AB (SE) | 2012-03-28 | — | — | EP | disclosed |
| US-20120065199-A1 | SUBSTITUTED QUINOLINES FOR USE AS VEGF INHIBITORS | CLANOTECH AB (SE) | 2012-03-15 | — | — | US | disclosed |
| US-20120065199-A1 | SUBSTITUTED QUINOLINES FOR USE AS VEGF INHIBITORS | CLANOTECH AB (SE) | 2012-03-15 | — | — | US | disclosed |
| US-20120065199-A1 | SUBSTITUTED QUINOLINES FOR USE AS VEGF INHIBITORS | CLANOTECH AB (SE) | 2012-03-15 | — | — | US | disclosed |
| WO-2010133669-A1 | SUBSTITUTED QUINOLINES FOR USE AS VEGF INHIBITORS | CLANOTECH AB (SE) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010133669-A1 | SUBSTITUTED QUINOLINES FOR USE AS VEGF INHIBITORS | CLANOTECH AB (SE) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031723-A1 | Quinoline Compounds Which Are Anti-Angiogenic Integrin Alpha5 Beta1 Inhibitors for Use in the Treatment of Fibrosis or Fibrosis-Related Diseases | ITGB5, ITGA5, ITGAL | TBXAS1 121/4885GAA 1857/4885MEN1 2381/4885 |
| US-20120065199-A1 | SUBSTITUTED QUINOLINES FOR USE AS VEGF INHIBITORS | FLT1, FLT4, VEGFA | TBXAS1 78/4885GAA 1641/4885MEN1 2837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.